Member Info for liquid1

Interesting Renx chart. Looks like we are seriously cheap! With FDA approval this stock is really gonna motor!

One of Nanoco’s main assets is its people

Nanoco’s team consists of highly qualified scientists, sales, operational and administrative staff recruited

from countries all around the world. In total the company has people spanning over 15 nationalities, testifying to the company’s hunger for the best and brightest.

With a Semi-Tech facility in Runcorn, UK, an office in Boston, US, and business

development managers working in the USA, Japan, Korea, China and Taiwan, Nanoco has an experienced team with a truly global outlook.

Nanoco has patented a unique technology for high volume production

Nanoco’s patented ‘molecular seeding’ process allows for the production of uniform, high quality quantum dots on a large scale.

Nanoco continues to expand its Semi-Tech production capacity to meet the increasing testing and sampling requirements of its customer base.

Nanoco has signed global licensing deals with Dow Electronic Materials, Merck and Wah Hong to service the display industry.

These deals allows our partners to utilize its expertise in high volume manufacturing to market and sell Nanoco’s CFQD® quantum dots for display applications.

Nanoco’s ability to innovate keeps it on the cutting edge of technology. The company’s large and growing patent portfolio helps maintain its position as industry front runners.

Nanoco’s core intellectual property revolves around four key areas: the company’s

proprietary mass production process, CFQD® quantum dot materials, surface chemistry and applications/devices incorporating its materials.

For example, Nanoco has patents surrounding the molecular seeding process for the production of high quality CFQD® quantum dots, cost effectively and on an industrial scale.

This process not only allows the company to produce on a large scale, it also offers precise control over the particle-size, enabling them to provide material to meet any defined specification.

All told, Nanoco now holds ca. 300 granted patents or pending patent applications in these four key areas.

Quantum dots are a true platform technology with applications in areas as diverse as flat screen displays, LED lighting and bio-imaging.

NANOCO quantum dots are differentiated from other quantum dot technologies as they do not contain toxic heavy-metals such as cadmium, a known carcinogen. Legislation limiting the use of heavy-metals is becoming increasingly restrictive, to protect consumers and the environment.

The EU’s RoHS Directive, for example, restricts the use of cadmium in materials such as liquids, plastics or coatings to maximum concentrations of 0.01% (100 ppm). Similar legislation is in the pipeline in countries such as China, Korea, Japan and the US.

Nanoco’s innovative technology allows for highly efficient quantum dots to be made that are completely cadmium and heavy-metal free. This uniquely positions Nanoco as one of the few manufacturers able to supply quantum dots which can be used without legislative restrictions on heavy metals content in a whole range of consumer electronics and lighting applications.

Agree looks overdone as usual! 15p sometime next week!

This will bounce into double digits next week! 32p to 8.5p because the contract expires year end! FFS the company is not bust!

Still 73% down Too cheap Oversold

Definitely oversold! Reminds me of MTFB: dropped to 5p from 39p and rose to 14p intraday

13 December 2018 IQ-AI Ltd ("IQ-AI" or the "Company") StoneChecker 510k Update IQ-AI are pleased to provide an update on the status of the StoneChecker software the US Food and Drug Administration ("FDA") application. StoneChecker continues to be reviewed by FDA and IQ-AI are awaiting feedback on testing methodology. StoneChecker was originally submitted to FDA in May 2018. Under the FDA's 510k guidelines, manufacturers are required to compare the new product to an existing FDA cleared product. This represented a challenge since StoneChecker has some unique features which are not found in other "predicate" products. A CT machine software was chosen to establish "substantial equivalence" to StoneChecker, but after several discussions with FDA it was mutually agreed that a different comparator device be used. Consequently, the 510k package was resubmitted to them and they formally accepted it on 22 August 2018. On 5 October 2018, we received correspondence from the FDA that the original package needed supplemental information and we were invited to discuss this with them to seek clarification. A conference call followed on 30 October 2018. During that call it seemed that the Agency clearly understood the purpose of StoneChecker but asked for additional information to be presented to show how the product might work in situations where suboptimal CT images had been obtained. The FDA wanted to be confident that StoneChecker could still provide reliable data output when attempting to analyse poor input data. The Company has gone back to the original clinical data that was developed to verify that this kind of data exists and has submitted a response to the FDA with a proposed test method outlined that, the Board believes, would satisfy them that StoneChecker will function under these more challenging conditions. This additional testing methodology was submitted to the FDA on 27 November 2018 for their evaluation.

Artificial Intelligence in Medicine Market Overview: The global artificial intelligence in medicines market was valued at $719 million in 2017 and is estimated to reach $18,119 million at a CAGR of 49.6% from 2018 to 2025. Artificial intelligence (AI) in medicine is used to analyze complex medical data by approximating human cognition with the help of algorithms and software. The development of novel pharmaceuticals and biologicals through clinical trials can take more than a decade and cost billions of dollars during that tenure period. AI technology can help to make this process faster and cheaper, which in turn is expected to help improve the efficiency of pharmaceutical and biotechnology companies. https://www.alliedmarketresearch.com/artificial-intelligence-in-medicine-market

A day closer to FDA approval

https://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker https://www.imagingbiometrics.com/what-we-offer/product-services/ib-clinic Watch the video : https://youtu.be/6BCSZIi5VQE Upbeat interview with the ceo last week with some insight.

To buy at 4.9p

https://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/

Over 60million trades over the last week, mostly buyers! Free float about 50million. Remember PYC rise when stock run out!

Cash2 Wake up bid at 4.1p

Good bye 4p

https://youtu.be/6BCSZIi5VQE

Video: CEO last week on FDA

MM's have no free float shares left!

Only 50% for 120m used up!